| Tumor
Angiogenesis and Vascularity Ballroom B Chairs: Michal Neeman and Hans Hawighorst |
| 10:30 142. In Vivo Prediction of Vascular Response to VEGF Withdrawal: Tracking Vascular Maturation by MRI, R. Abramovitch, H. Dafni, E. Smouha, L.E. Benjamin and M. Neeman, Weizmann Institute of Science, Rehovot, Israel; Hebrew University and Hadassah Medical School, Jerusalem, Israel. |
| 10:42 143. What is the Effect of Tumoral VEGF Overproduction on MR Imaging? M. Lewin, S. Bredow, N. Sergeyev, E. Marecos, A. Bogdanov Jr and R. Weissleder, Massachusetts General Hospital, Charlestown, MA, USA. |
| 10:54 144. Rapid, One-Step Antibody-Targeted Magnetic Resonance Contrast Enhancement of Neovascular avb3 Epitopes using a Nanoparticulate Emulsion, S.A. Anderson, R.K. Rader, W.F. Westlin, C. Null, G.M. Lanza, S.A. Wickline and J.J. Kotyk, Monsanto Company and Washington University, St. Louis, MO, USA. |
| 11:06 145. Prediction of Gene Therapy Induced Volumetric Changes by Intravascular Volume Changes Measured Using Dynamic Contrast Enhanced MRI, M-Y. Su, J.A. Taylor, L.P. Villarreal and O. Nalcioglu, University of California, Irvine, CA, USA. |
| 11:18 146. Comparison of Vascular Volume and Permeability for Tumors Derived from Metastatic Human Breast Cancer Cells With and Without the Metastasis Suppressor Gene nm23, Z.M. Bhujwalla, D. Artemov, M. Solaiyappan, D. Mao and J.P. Backer, The Johns Hopkins University School of Medicine, Baltimore, MD, USA and New York Medical College, Valhalla, NY, USA. |
| 11:30 147. Gd-DTPA Uptake Rates are Linearly Related to the Perfused Microvessel Density and Surface-Area in 9L-Glioma Rat Models, B.P.J. van der Sanden, T.H. Rozijn, P.F.J.W. Rijken, H.P.W. Peters, A. Heerschap, A.J. van der Kogel and W.M.M.J. Bovée, Academic Hospital, Nijmegen, The Netherlands and Delft University of Technology, Delft, The Netherlands. |
| 11:42 148. Measurement of Blood Flow, Blood Volume and Capillary Permeability in a Canine Spontaneous Breast Tumour Model Using Two Different Contrast Agents, E. Henderson, J. Sykes, D. Drost, H-J. Weinmann, B.K. Rutt and T-Y. Lee, St. Joseph's Health Centre, The University of Western Ontario and Robarts Research Institute, London, ON, Canada and Schering Research Laboratories, Berlin, Germany. |
| 11:54 149. Utility of Acquiring Vascular Blood Volume, Permeability and Morphology Information from Dynamic Susceptibility Contrast Agent Studies in Patients with Brain Tumors, K.M. Donahue, A. Pathak, S. Rand, R. Prost and H. Krouwer, Medical College of Wisconsin, Milwaukee, WI, USA. |
| 12:06 150. Quantitative CBF Mapping on Brain Tumor Patients Using Multislice Perfusion Imaging with Pulsed Arterial Spin-Labeling, Y. Yang, B.K. Lewis, S. Xu, J.A. Frank and J.H. Duyn, National Institutes of Health, Bethesda, MD, USA. |
| 12:18 151. Abnormalities of the Contrast Re-circulation Phase in Cerebral Tumours Demonstrated using Dynamic Susceptibility Contrast-enhanced MR Imaging: A Possible Marker of Vascular Tortuosity, A. Kassner, D. Annesley, X.P. Zhu, K.L. Li, I.D. Kamaly-Asl, Y. Watson and A. Jackson, Philips Medical Systems, London, UK; University of Manchester and Central Manchester Healthcare Trust, Manchester, UK. |